Browsing by Author "Aljabali, Alaa A. A."

Now showing 1 - 5 of 5
  • No Thumbnail Available
    Item
    Albumin Nano-Encapsulation of Piceatannol Enhances Its Anticancer Potential in Colon Cancer Via Downregulation of Nuclear p65 and HIF-1α
    (2020) Aljabali, Alaa A. A.; Bakshi, Hamid A.; Hakkim, Faruck L.; Haggag, Yusuf A.; Al-Batanyeh, Khalid M.; Al Zoubi, Mazhar S.; Al-Trad, Bahaa; Nasef, Mohamed M.; Satija, Saurabh; Mehta, Meenu; Pabreja, Kavita; Mishra, Vijay; Khan, Mohammed; Abobaker, Salem; Azzouz, Ibrahim M.; Dureja, Harish; Pabari, Ritesh M.; Dardouri, Ashref Ali K.; Kesharwani, Prashant; Gupta, Gaurav; Shukla, Shakti Dhar; Prasher, Parteek; Charbe, Nitin B.; Negi, Poonam; Kapoor, Deepak N.; Chellappan, Dinesh Kumar; da Silva, Mateus Webba; Thompson, Paul; Dua, Kamal; McCarron, Paul; Tambuwala, Murtaza M.
    Piceatannol (PIC) is known to have anticancer activity, which has been attributed to its ability to block the proliferation of cancer cells via suppression of the NF-kB signaling pathway. However, its effect on hypoxia-inducible factor (HIF) is not well known in cancer. In this study, PIC was loaded into bovine serum albumin (BSA) by desolvation method as PIC-BSA nanoparticles (NPs). These PIC-BSA nanoparticles were assessed for in vitro cytotoxicity, migration, invasion, and colony formation studies and levels of p65 and HIF-1 alpha. Our results indicate that PIC-BSA NPs were more effective in downregulating the expression of nuclear p65 and HIF-1 alpha in colon cancer cells as compared to free PIC. We also observed a significant reduction in inflammation induced by chemical colitis in mice by PIC-BSA NPs. Furthermore, a significant reduction in tumor size and number of colon tumors was also observed in the murine model of colitis-associated colorectal cancer, when treated with PIC-BSA NPs as compared to free PIC. The overall results indicate that PIC, when formulated as PIC-BSA NPs, enhances its therapeutic potential. Our work could prompt further research in using natural anticancer agents as nanoparticels with possible human clinical trails. This could lead to the development of a new line of safe and effective therapeutics for cancer patients.
  • No Thumbnail Available
    Item
    An overview of vaccine development for COVID-19
    (2021) Shahcheraghi, Seyed H.; Ayatollahi, Jamshid; Aljabali, Alaa A. A.; Shastri, Madhur D.; Shukla, Shakti D.; Chellappan, Dinesh K.; Jha, Niraj K.; Anand, Krishnan; Katari, Naresh K.; Mehta, Meenu; Satija, Saurabh; Dureja, Harish; Mishra, Vijay; Almutary, Abdulmajeed G.; Alnuqaydan, Abdullah M.; Charbe, Nitin; Prasher, Parteek; Gupta, Gaurav; Dua, Kamal; Lotfi, Marzieh; Bakshi, Hamid A.; Tambuwala, Murtaza M.
    The COVID-19 pandemic continues to endanger world health and the economy. The causative SARS-CoV-2 coronavirus has a unique replication system. The end point of the COVID-19 pandemic is either herd immunity or widespread availability of an effective vaccine. Multiple candidate vaccines - peptide, virus-like particle, viral vectors (replicating and nonreplicating), nucleic acids (DNA or RNA), live attenuated virus, recombinant designed proteins and inactivated virus - are presently under various stages of expansion, and a small number of vaccine candidates have progressed into clinical phases. At the time of writing, three major pharmaceutical companies, namely Pfizer and Moderna, have their vaccines under mass production and administered to the public. This review aims to investigate the most critical vaccines developed for COVID-19 to date.
  • No Thumbnail Available
    Item
    Dietary Crocin is Protective in Pancreatic Cancer while Reducing Radiation-Induced Hepatic Oxidative Damage
    (2020) Bakshi, Hamid A.; Al Zoubi, Mazhar S.; Faruck, Hakkim L.; Aljabali, Alaa A. A.; Rabi, Firas A.; Hafiz, Amin A.; Al-Batanyeh, Khalid M.; Al-Trad, Bahaa; Ansari, Prawej; Nasef, Mohamed M.; Charbe, Nitin B.; Satija, Saurabh; Mehta, Meenu; Mishra, Vijay; Gupta, Gaurav; Abobaker, Salem; Negi, Poonam; Azzouz, Ibrahim M.; Dardouri, Ashref Ali K.; Dureja, Harish; Prasher, Parteek; Chellappan, Dinesh K.; Dua, Kamal; Da Silva, Mateus Webba; El Tanani, Mohamed; McCarron, Paul A.; Tambuwala, Murtaza M.
    Pancreatic cancer is one of the fatal causes of global cancer-related deaths. Although surgery and chemotherapy are standard treatment options, post-treatment outcomes often end in a poor prognosis. In the present study, we investigated anti-pancreatic cancer and amelioration of radiation-induced oxidative damage by crocin. Crocin is a carotenoid isolated from the dietary herb saffron, a prospect for novel leads as an anti-cancer agent. Crocin significantly reduced cell viability of BXPC3 and Capan-2 by triggering caspase signaling via the downregulation of Bcl-2. It modulated the expression of cell cycle signaling proteins P53, P21, P27, CDK2, c-MYC, Cyt-c and P38. Concomitantly, crocin treatment-induced apoptosis by inducing the release of cytochrome c from mitochondria to cytosol. Microarray analysis of the expression signature of genes induced by crocin showed a substantial number of genes involved in cell signaling pathways and checkpoints (723) are significantly affected by crocin. In mice bearing pancreatic tumors, crocin significantly reduced tumor burden without a change in body weight. Additionally, it showed significant protection against radiation-induced hepatic oxidative damage, reduced the levels of hepatic toxicity and preserved liver morphology. These findings indicate that crocin has a potential role in the treatment, prevention and management of pancreatic cancer.
  • Thumbnail Image
    Item
    Hybrid molecules based on 1,3,5-triazine as potential therapeutics: A focused review
    (2020) Prasher, P.; Sharma, M.; Aljabali, Alaa A. A.; Gupta, G.; Negi, P.; Kapoor, D. N.; Singh, I.; Zacconi, Flavia C. M.; Andreoli Pinto, T. de J.; Webba da Silva, M.; Bakshi, H.; Chellappan, D. K.; Tambuwala, M. M.; Dua, K.
    Majority of the representative drugs customarily interact with multiple targets manifesting unintended side effects. In addition, drug resistance and over expression of the cellular efflux-pumps render certain classes of drugs ineffective. With only a few innovative formulations in development, it is necessary to identify pharmacophores and novel strategies for creating new drugs. The conjugation of dissimilar pharmacophoric moieties to design hybrid molecules with an attractive therapeutic profile is an emerging paradigm in the contemporary drug development regime. The recent decade witnessed the remarkable biological potential of 1,3,5-triazine framework in the development of various chemotherapeutics. The appending of the 1,3,5-triazine nucleus to biologically relevant moieties has delivered exciting results. The present review focuses on 1,3,5-triazine based hybrid molecules in the development of pharmaceuticals.
  • No Thumbnail Available
    Item
    Targeting LIN28: a new hope in prostate cancer theranostics
    (2021) Shrivastava, Garima; Aljabali, Alaa A. A.; Shahcheraghi, Seyed Hossein; Lotfi, Marzieh; Shastri, Madhur D.; Shukla, Shakti D.; Chellappan, Dinesh K.; Jha, Niraj Kumar; Anand, Krishnan; Dureja, Harish; Pabari, Ritesh M.; Mishra, Vijay; Almutary, Abdulmajeed G.; Alnuqaydan, Abdullah M.; Charbe, Nitin; Prasher, Parteek; Negi, Poonam; Goyal, Rohit; Dua, Kamal; Gupta, Gaurav; Serrano-Aroca, Angel; Bahar, Bojlul; Barh, Debmalya; Panda, Pritam Kumar; Takayama, Kazuo; Lundstorm, Kenneth; McCarron, Paul; Bakshi, Hamid; Tambuwala, Murtaza M.
    The mortality and morbidity rates for prostate cancer have recently increased to alarming levels, rising higher than lung cancer. Due to a lack of drug targets and molecular probes, existing theranostic techniques are limited. Human LIN28A and its paralog LIN28B overexpression are associated with a number of tumors resulting in a remarkable increase in cancer aggression and poor prognoses. The current review aims to highlight recent work identifying the key roles of LIN28A and LIN28B in prostate cancer, and to instigate further preclinical and clinical research in this important area.